Suffolk Capital Management LLC lessened its stake in shares of Revance Therapeutics Inc (NASDAQ:RVNC) by 55.4% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 23,661 shares of the biopharmaceutical company’s stock after selling 29,436 shares during the quarter. Suffolk Capital Management LLC owned about 0.07% of Revance Therapeutics worth $846,000 as of its most recent filing with the SEC.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in RVNC. Jennison Associates LLC boosted its stake in shares of Revance Therapeutics by 127.1% during the 4th quarter. Jennison Associates LLC now owns 857,536 shares of the biopharmaceutical company’s stock worth $30,657,000 after acquiring an additional 480,008 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Revance Therapeutics by 7.3% during the 2nd quarter. Vanguard Group Inc. now owns 931,623 shares of the biopharmaceutical company’s stock worth $24,595,000 after acquiring an additional 63,505 shares in the last quarter. Northern Trust Corp boosted its stake in shares of Revance Therapeutics by 19.9% during the 2nd quarter. Northern Trust Corp now owns 318,877 shares of the biopharmaceutical company’s stock worth $8,418,000 after acquiring an additional 52,940 shares in the last quarter. Pura Vida Investments LLC bought a new stake in shares of Revance Therapeutics during the 3rd quarter worth about $1,378,000. Finally, EAM Investors LLC boosted its stake in shares of Revance Therapeutics by 113.9% during the 3rd quarter. EAM Investors LLC now owns 72,518 shares of the biopharmaceutical company’s stock worth $1,998,000 after acquiring an additional 38,621 shares in the last quarter. Institutional investors own 77.84% of the company’s stock.
In related news, CEO L Daniel Browne sold 7,600 shares of the stock in a transaction that occurred on Wednesday, November 22nd. The stock was sold at an average price of $24.94, for a total transaction of $189,544.00. Following the completion of the sale, the chief executive officer now owns 133,188 shares in the company, valued at approximately $3,321,708.72. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 18.86% of the stock is owned by corporate insiders.
Several research firms have recently issued reports on RVNC. Guggenheim reiterated a “neutral” rating and set a $42.00 price target on shares of Revance Therapeutics in a research note on Thursday, January 4th. Mizuho reiterated a “buy” rating and set a $54.00 price target on shares of Revance Therapeutics in a research note on Friday, January 5th. Cantor Fitzgerald set a $50.00 price target on Revance Therapeutics and gave the stock a “buy” rating in a research note on Thursday, January 4th. Barclays set a $40.00 target price on Revance Therapeutics and gave the company a “buy” rating in a research note on Tuesday, December 19th. Finally, Cowen set a $55.00 target price on Revance Therapeutics and gave the company a “buy” rating in a research note on Wednesday, January 17th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the company’s stock. Revance Therapeutics has a consensus rating of “Buy” and a consensus target price of $44.30.
Shares of Revance Therapeutics Inc (NASDAQ RVNC) opened at $31.20 on Friday. Revance Therapeutics Inc has a 52 week low of $18.00 and a 52 week high of $37.45.
TRADEMARK VIOLATION NOTICE: This article was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this article can be read at https://ledgergazette.com/2018/02/17/revance-therapeutics-inc-rvnc-stake-lessened-by-suffolk-capital-management-llc.html.
Revance Therapeutics Company Profile
Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.
Want to see what other hedge funds are holding RVNC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Revance Therapeutics Inc (NASDAQ:RVNC).
Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.